2256 — Abbisko Medicine Share News
0.000.00%
Last trade - 00:00- HK$4.55bn
- HK$2.21bn
- CNY612.12m
Brief: Abbisko Cayman Subscribes $10 Mln In Callable Zero Coupon Notes
Brief: Abbisko Cayman Says CDE Of NMPA Clears Ind For Abbisko's Pd-L1 Inhibitor Combo For NSCLC
Brief: Abbisko Cayman Posts H1 Revenue RMB 657.1 Million
Brief: Abbisko Cayman's Founder Purchases Total Of 17,000 Ordinary Shares Of Co
Brief: Abbisko Cayman Says Criticism Irrelevant To Affairs Of Group
Brief: Abbisko Cayman Ltd Says China NMPA Acceptance Of NDA For Pimicotinib For Treatment Of TGCT
Brief: Abbisko Cayman Says Abbisko Therapeutics Receives $85Mn From Merck
Brief: Abbisko Cayman Says CDE Approval Of Breakthrough Therapy Designation For Irpagratinib (Absk011)
Brief: Abbisko Cayman Says Merck's Exercise Of Global Option For Pimicotinib
Brief: Abbisko Cayman Receives IND Clearance From CDE Of NMPA China For ABSK061
Brief: Abbisko Cayman Says Abbisko Therapeutics & Allist Enter Cooperation Agreement
Brief: Abbisko Cayman Says CEO Purchased A Total Of 40,000 Ordinary Shares Of Co
Brief: Abbisko Cayman Says Center For Drug Evaluation Cleared IND Application For Absk131
Brief: Abbisko Cayman's Founder, Executive Director, CEO & Chairman Purchased Total Of 45,000 Ordinary Shares
China's Abbisko Cayman near 3-year peak on share buyback plan
Brief: Abbisko Cayman Announces On-Market Share Repurchase Of No More Than HKD200 Million
Brief: Abbisko Cayman Says Positive Top-Line Results From Phase 3 Maneuver Study Of Pimicotinib In TGCT Patients
Brief: Abbisko Cayman Says As Of Sept 30, Co Has Cumulatively Repurchased 22.6 Million Shares
Brief: Abbisko Cayman Says ABK3376 Obtained IND Approval From NMPA